https://scholars.lib.ntu.edu.tw/handle/123456789/605989
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Lee J.-J | en_US |
dc.contributor.author | Liao A.T | en_US |
dc.contributor.author | TAI-CHING LIAO | en_US |
dc.contributor.author | JIH-JONG LEE | en_US |
dc.contributor.author | SHANG-LIN WANG | en_US |
dc.creator | Lee J.-J;Liao A.T;Wang S.-L. | - |
dc.date.accessioned | 2022-04-25T03:57:47Z | - |
dc.date.available | 2022-04-25T03:57:47Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 20762615 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111021129&doi=10.3390%2fani11082199&partnerID=40&md5=9652ac7f5c635d03cb7e8d8ffee926db | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/605989 | - |
dc.description.abstract | Cyclophosphamide exhibits the weakest therapeutic effect compared with vincristine and doxorubicin in the CHOP (C, cyclophosphamide; H, doxorubicin; O, vincristine; and P, prednisolone) chemotherapeutic protocol for the treatment of canine lymphoma. Twenty dogs with multicentric lymphoma were treated using the LHOP protocol, which used l-asparaginase in place of cyclophos-phamide, and the outcomes were historically compared with those of dogs that received CHOP chemotherapy in the same institution. No significant differences were found in age (p = 0.107), body weight (p = 0.051), sex (p = 0.453), clinical stage V (p = 1), substage b (p = 0.573), T-cell phenotype (p = 0.340), overall response (p = 1), and hypercalcaemia status (p = 1) between the LHOP and CHOP groups. The adverse effects of l-asparaginase were well tolerated and self-limiting. The median PFS (progression-free survival) and median ST (survival time) in the LHOP group were 344 days (range: 28–940 days) and 344 days (range: 70–940 days), respectively. The median PFS and median ST in the CHOP group were 234 days (range: 49–1822 days) and 314 days (range: 50–1822 days), respectively. The dogs that received LHOP chemotherapy had a significantly longer PFS than the dogs that received CHOP chemotherapy (p = 0.001). No significant difference was observed in ST between the LHOP and CHOP groups (p = 0.131). Our study findings thus indicate that the LHOP protocol can be used as a first-line chemotherapeutic protocol in canine multicentric lymphoma. ? 2021 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.relation.ispartof | Animals | - |
dc.subject | Canine | - |
dc.subject | L-asparaginase | - |
dc.subject | Lymphosarcoma | - |
dc.subject | Oncology | - |
dc.subject | Outcome | - |
dc.title | Article l-asparaginase, doxorubicin, vincristine, and prednisolone (Lhop) chemotherapy as a first-line treatment for dogs with multicentric lymphoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.3390/ani11082199 | - |
dc.identifier.scopus | 2-s2.0-85111021129 | - |
dc.relation.journalvolume | 11 | - |
dc.relation.journalissue | 8 | - |
item.openairetype | journal article | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
crisitem.author.dept | Veterinary Medicine | - |
crisitem.author.dept | Molecular and Comparative Pathobiology | - |
crisitem.author.dept | Veterinary Clinical Sciences | - |
crisitem.author.dept | Veterinary Clinical Sciences | - |
crisitem.author.orcid | 0000-0002-8696-8180 | - |
crisitem.author.orcid | 0000-0002-4424-730X | - |
crisitem.author.orcid | 0000-0002-2390-1632 | - |
crisitem.author.parentorg | College of Bioresources and Agriculture | - |
crisitem.author.parentorg | College of Bioresources and Agriculture | - |
crisitem.author.parentorg | College of Bioresources and Agriculture | - |
crisitem.author.parentorg | College of Bioresources and Agriculture | - |
顯示於: | 獸醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。